All News
Future Big BiTEs (6.28.2024)
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.
Read Article
Factors Affecting Hydroxychloroquine Adherence
A study from the University of British Columbia has evaluated the trajectories of hydroxychloroquine (HCQ) use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence.
Read Article
Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis
A multicenter cohort study of systemic lupus erythematosus patients with type 2 diabetes has shown the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors associated with a significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality compared with no SGLT2i use.
Read Article
New indications for JAK inhibitors
There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.
Read Article
EULAR 2024 Rheumatology Roundup (6.21.2024)
Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna
Read Article
Study of 2,974 SLE pts taking hydroxychloroquine (HCQ) found 584 w/ ≥1 hospitalization for SLE. Taking Lower doses of HCQ (≤5 mg/kg/d) or <400 mg/d were assoc w/ increased hospitalizations for active SLE (adjusted OR 4.20 & aOR 3.39, respectively) https://t.co/QbLBMtBO30 https://t.co/b63bC0SKsf
Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/7hJeTf3O6y https://t.co/V43YHjhEhn
Dr. John Cush RheumNow ( View Tweet)
RT @yuz6yusof #EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) #EULARBEST
Dr. John Cush RheumNow ( View Tweet)
Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis
https://t.co/QKXUxyhPUd https://t.co/Lx0VrBGqtg
Dr. John Cush RheumNow ( View Tweet)
RT @yuz6yusof #EULAR2024 OP0043 Data from UK BILAG-BR registry showed in n>100 patients w neuropsychiatric #lupus (NPSLE), over 2/3 improved with rituximab. NPSLE tended to occur with other #SLE features and with high level of organ damage @RheumNow https://t.co/45OM0PLtjM
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 387 lupus nephritis pts found pulmonary HTN in 15%. An increased risk of PH was seen w/ eGFR <30, and w/ low Hgb, low triglycerides. PH was independently associated with a higher risk (HR ~ 2.0) of all-cause mortality and adverse renal outcomes https://t.co/hdLjOZc9TI https://t.co/60lhdo93lm
Dr. John Cush RheumNow ( View Tweet)
Study of 2,974 SLE pts taking hydroxychloroquine (HCQ) found 584 w/ ≥1 hospitalization for SLE. Taking Lower doses of HCQ (≤5 mg/kg/d) or <400 mg/d were assoc w/ increased hospitalizations for active SLE (adjusted OR 4.20 & aOR 3.39, respectively) https://t.co/xXLiGFoU3L https://t.co/Sy36aOG81Y
Dr. John Cush RheumNow ( View Tweet)
9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024
Dr. John Cush RheumNow ( View Tweet)
Tapering Treatment for Lupus
Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus.
https://t.co/ijy5OwIoCe https://t.co/7yQIxW70Zd
Dr. John Cush RheumNow ( View Tweet)
Cognitive Function in Older Adults: Worse in Lupus
Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.
https://t.co/zedGdNbHw4 https://t.co/DIHvkEZRVk
Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f
Dr. John Cush RheumNow ( View Tweet)
Damage in Childhood Lupus
Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise.
https://t.co/wCygK0LGvd https://t.co/tm8LTI28mh
Dr. John Cush RheumNow ( View Tweet)
We've Got to Talk about CAR T cells
Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria.
https://t.co/mrr5MWxeJz https://t.co/0FMLaAxaWV
Dr. John Cush RheumNow ( View Tweet)
Update on low-dose glucocorticoids in SLE
GC have been the mainstay of treatment in SLE for nearly 75 yrs. GC induce anti-inflammatory effects, quickly relieve symptoms, and reduce mortality in life-threatening flares through various actions.
https://t.co/uEtWftvwEz https://t.co/nJlpELMj5W
Dr. John Cush RheumNow ( View Tweet)
Is a Biomarker for Adverse Pregnancy Outcomes on the Horizon?
Pregnancy in lupus patients raises concerns due to potential complications like preeclampsia, eclampsia, and increased mortality rates for both mother and baby.
https://t.co/Kv6F21UHze https://t.co/ya8lAkSLC2
Dr. John Cush RheumNow ( View Tweet)
